Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Hee Ryung | - |
dc.contributor.author | Woo, Young Sup | - |
dc.contributor.author | Ahn, Hyeong Sik | - |
dc.contributor.author | Ahn, Il Min | - |
dc.contributor.author | Kim, Hyun Jung | - |
dc.contributor.author | Bahk, Won-Myong | - |
dc.date.accessioned | 2021-09-04T15:30:54Z | - |
dc.date.available | 2021-09-04T15:30:54Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-06 | - |
dc.identifier.issn | 1461-1457 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/93391 | - |
dc.description.abstract | Background: Atypical antipsychotic augmentation was demonstrated to be efficacious in treatment-resistant depression (TRD) in previous meta-analyses. We investigate whether there are differences in the effect size of atypical antipsychotic augmentation in major depressive disorder according to the degree of treatment resistance. Methods: A comprehensive search of four databases identified 11 randomized controlled trials. The 11 trials, which included 3 341 participants, were pooled using a random-effects meta-analysis. Results: Atypical antipsychotic augmentation of antidepressant therapy showed superior efficacy compared to antidepressant monotherapy in TRD in terms of both response and remission rates (response, risk ratio [RR] = 1.38, 95% confidence interval [CI] = 1.25 to 1.53; remission, RR = 1.62, 95% CI = 1.42 to 1.85). In addition, regarding response rates in the TRD trials, atypical antipsychotic augmentation exhibited significantly different effect sizes according to the degree of treatment resistance (TRD 1: RR = 1.24; TRD 2: RR = 1.37; TRD 2-4: RR = 1.58). In non-TRD trials, atypical antipsychotic augmentation failed to show superior efficacy over antidepressant monotherapy in terms of remission rates (RR = 0.89; 95% CI = 0.69 to 1.14). Atypical antipsychotic augmentation of antidepressant therapy exhibits greater effect size in patients with a higher degree of treatment resistance. Conclusions: This finding strengthens the rationale for considering atypical antipsychotic augmentation among depressed patients with multiple previous treatment failures in clinical practice. The efficacy of atypical antipsychotic augmentation for non-TRD seems to be different from that for TRD and, thus, further studies of non-TRD populations are needed. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.subject | EXTENDED-RELEASE QUETIAPINE | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | ADJUNCTIVE THERAPY | - |
dc.subject | ARIPIPRAZOLE AUGMENTATION | - |
dc.subject | ANTIDEPRESSANT TREATMENT | - |
dc.subject | LITHIUM AUGMENTATION | - |
dc.subject | INADEQUATE-RESPONSE | - |
dc.subject | DISORDER | - |
dc.subject | MULTICENTER | - |
dc.title | Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ahn, Hyeong Sik | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Jung | - |
dc.identifier.doi | 10.1093/ijnp/pyv023 | - |
dc.identifier.scopusid | 2-s2.0-84931271037 | - |
dc.identifier.wosid | 000359703500010 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, v.18, no.8 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | - |
dc.citation.volume | 18 | - |
dc.citation.number | 8 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | EXTENDED-RELEASE QUETIAPINE | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | ADJUNCTIVE THERAPY | - |
dc.subject.keywordPlus | ARIPIPRAZOLE AUGMENTATION | - |
dc.subject.keywordPlus | ANTIDEPRESSANT TREATMENT | - |
dc.subject.keywordPlus | LITHIUM AUGMENTATION | - |
dc.subject.keywordPlus | INADEQUATE-RESPONSE | - |
dc.subject.keywordPlus | DISORDER | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordAuthor | atypical antipsychotics | - |
dc.subject.keywordAuthor | augmentation | - |
dc.subject.keywordAuthor | major depressive disorder | - |
dc.subject.keywordAuthor | treatment resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.